Clinical efficacy of robotic pancreaticoduodenectomy in treatment of periampullary carcinoma
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 4
Abstract
"<b>Objective</b> To investigate the clinical application and efficacy of Da Vinci robotic assisted pancreaticoduodenectomy (RPD) in treatment of periampullary carcinoma（PAC）. <b>Methods</b> The clinical data of 8 patients with PAC (5 cases of pancreatic head adenocarcinoma, 2 cases of duodenal adenocarcinoma, and 1 case of adenocarcinoma of the lower bile duct) admitted to Yancheng First Peoples Hospital from December 2021 to June 2023 were retrospectively analyzed. There were 4 males and 4 females, aged (63±10) years，and all of them were treated with RPD. The patients status during and after operation, and at follow-up were observed, with the follow-up time until June 2023. <b>Results</b> Eight patients successfully completed RPD, without any conversion to open surgery. The surgery time was (358±68) min, and the intraoperative blood loss was (240±112) mL. Only one patients received intraoperative allogeneic blood transfusion. All patients had negative pathological margins and achieved R0 resection. The time to gastric tube extraction, time to initial diet intake, time for getting out of bed and postoperative hospital stay of 8 patients were (3.6±1.1), (2.8±0.6), (2.6±0.4) and (20.8±4.2) days, respectively. There was no secondary operation and no perioperative death. Six cases had perioperative complications (some cases complicated with multiple complications), including 4 cases of mild pancreatic leakage, 1 case of biliary leakage, 3 cases of pleural or abdominal effusion,1 case of intestinal retention,and 1 case of gastric obstruction, all of which were cured after symptomatic conservative treatment. All 8 cases received a median follow-up of 10 months, with 2 cases experiencing tumor recurrence and metastasis, and 6 cases without recurrence and metastasis . One case died due to pulmonary embolism,and 7 cases entered the adjuvant chemotherapy procedure after surgery and all survived, with good living conditions. <b>Conclusion</b> RPD is safe and feasible for the treatment of PAC,and can be applied individually and reasonably.However, long-term prognosis evaluation requires large-size, high-quality clinical studies."
Authors and Affiliations
LI Zuoan*, ZHANG Xiaoyan, XU Liqun, XU Yonghua, AN Hongyin, ZHA Wenzhang
Keywords
Related Articles
- EP ID EP734609
- DOI 10.13429/j.cnki.cjcr.2024.04.012
- Views 31
- Downloads 0
Research progress in sensitivity to inhalation anesthetics
Inhalation anesthetics have both sedative, analgesic and muscle relaxing effects,and are widely used in clinical practice. Hypersensitivity to inhalation anesthetics predicts poor postoperative outcomes. Current studies...
Changes and significance of α kinase 1 expression in cartilage tisssueof patients with knee osteoarthritis
<b>Objective</b> To investigate the expression changes and significance of α kinase 1 （ALPK1）, a member of the α kinase family, in cartilage tissue of knee osteoarthritis （OA）. <b>Methods</b> Twenty-five patients...
Claudin18.2： an emerging target for the treatment of gastric cancer
Gastric cancer is a malignant tumor that seriously endangers human health. Claudin18.2 (CLDN18.2) is a transmembrane protein and a main component of tight junctions that plays an important role in maintaining barrier fun...
Progress in clinical application of esketamine in pediatric anesthesia
Ketamine is a commonly used anesthetic drug, but its clinical use declined in the late 1990s due to its postoperative nightmares, extrapyramidal syndrome, and a tendency to abuse. As an isomer of ketamine, esketamine is...
Symptom clusters in patients with hypertensive cerebral haemorrhage during the acute phase and their correlation with prognostic quality of life
<b>Objective</b> To explore the composition of symptom clusters in the acute phase of patients with hypertensive cerebral haemorrhage and to analyse their correlation with prognostic quality of life. <b>Methods</b> From...